Aegerion Pharmaceuticals Announces Pricing of Initial Public Offering

BRIDGEWATER, N.J., Oct. 22, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $9.50 per share, before underwriting discounts and commissions. All shares are being sold by the company. Aegerion has granted the underwriters an option for 30 days to purchase up to an additional 750,000 shares at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The common stock will trade on the NASDAQ under the symbol "AEGR."

Leerink Swann LLC and Lazard Capital Markets LLC are acting as joint book-running managers for the offering. Needham & Company, LLC, Canaccord Genuity Inc. and Collins Stewart LLC are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from Leerink Swann LLC by mail at One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, or by calling toll free (800) 808-7525, Ext. 4814, or Lazard Capital Markets LLC by mail at 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, Attention: Syndicate Department, or by calling toll free (800) 542-0970

Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc.
Cardiovascular drug development

Downloads

DownloadFull Press Release

Latest News

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera